Literature DB >> 19111900

Amyloid beta concentrations in older people with Down syndrome and dementia.

Emma L Jones1, Marisa Hanney, Paul T Francis, Clive G Ballard.   

Abstract

People with Down syndrome develop Alzheimer's disease with an early age of onset. Plasma amyloid beta (Abeta) levels were measured in individuals with Down syndrome who were over the age of 40. No associations between age and Abeta1-40 and Abeta1-42 concentrations were found and nor were Abeta1-40 and Abeta1-42 levels found to vary between those with Alzheimer's-type dementia and those without dementia. The APOE genotype was not found to have an impact upon Abeta1-40 or Abeta1-42 concentrations. These data suggest that other factors play important roles in determining the onset and progression of dementia in the Down syndrome population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111900     DOI: 10.1016/j.neulet.2008.12.030

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

2.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

3.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 4.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

5.  Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome.

Authors:  Nicole Schupf; Annie Lee; Naeun Park; Lam-Ha Dang; Deborah Pang; Alexander Yale; David Kyung-Taek Oh; Sharon J Krinsky-McHale; Edmund C Jenkins; José A Luchsinger; Warren B Zigman; Wayne Silverman; Benjamin Tycko; Sergey Kisselev; Lorraine Clark; Joseph H Lee
Journal:  Neurobiol Aging       Date:  2015-06-19       Impact factor: 4.673

Review 6.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

7.  Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review.

Authors:  Melissa E Petersen; Sid E O'Bryant
Journal:  Dev Neurobiol       Date:  2019-09-03       Impact factor: 3.964

Review 8.  A Review of Biomarkers for Alzheimer's Disease in Down Syndrome.

Authors:  Ni-Chung Lee; Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  Neurol Ther       Date:  2017-07-21

9.  Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

Authors:  Carla M Startin; Nicholas J Ashton; Sarah Hamburg; Rosalyn Hithersay; Frances K Wiseman; Kin Y Mok; John Hardy; Alberto Lleó; Simon Lovestone; Lucilla Parnetti; Henrik Zetterberg; Abdul Hye; André Strydom
Journal:  Alzheimers Res Ther       Date:  2019-03-21       Impact factor: 6.982

10.  Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.

Authors:  Falah Alhajraf; Deborah Ness; Abdul Hye; Andre Strydom
Journal:  Dev Neurobiol       Date:  2019-09-11       Impact factor: 3.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.